‘Proton therapy increases survival rate of liver cancer patients’

Researchers at the National Cancer Center (NCC) have confirmed that proton therapy can increase the survival rate of both early and advanced liver cancer.

The team, led by Professors Kim Tae-hyun, Park Jung-won and Kim Bo-hyun, came to such conclusion after analyzing 243 patients who received proton therapy from June 2012 to April 2017.

The five-year survival rate of patients with proton therapy was 69 percent for patients with stage 1 liver cancer group and 65 percent for patients with stage 2 liver cancer. The rate was similar to that of other surgeries or high-frequency therapy, but significant for those patients who cannot receive surgery due to tumor location, size, recurrence, and accompanying disease such as old age, renal dysfunction.

The five-year survival rate was also 43 and 26 percent, respectively, for patients with stage 3 and 4 liver cancer.

The result was higher than the survival rates of other liver cancer treatments, indicating that proton therapy is effective in treating liver cancer in all stages. Also, none of the subjects had severe liver dysfunction due to proton therapy.


Patient specific outcomes of charged particle therapy for hepatocellular carcinoma – A systematic review and quantitative analysis

Piotr Spychalskia, Jarek Kobielaa, Magdalena Antoszewskaa, Agata Błażyńska-Spychalskaa, Barbara A. Jereczek-Fossac, Morten Høyerb

Hepatocellular carcinoma (HCC) is a raising condition world-wide. Most of patients are ineligible for surgery at diagnosis due to the advanced stage of the disease or poor medical condition of the patient. Charged particle therapy (CPT) is a radiotherapy modality showing promising results. The aim of this systematic review was to summarize current knowledge on patient-specific outcomes of CPT for HCC, including overall survival, local control, the effect of radiation dose and the toxicity burden (…)


CPT offers high local control, acceptable overall survival and low post-treatment morbidity. Quality of findings, especially on toxicities, is decreased by incomplete reporting and retrospective designs of available studies. Therefore, there is a strong need for better reporting and prospective studies.